These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22074713)

  • 21. Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies.
    Ouattara EN; Robine M; Eholié SP; MacLean RL; Moh R; Losina E; Gabillard D; Paltiel AD; Danel C; Walensky RP; Anglaret X; Freedberg KA
    Clin Infect Dis; 2016 Jun; 62(11):1454-1462. PubMed ID: 26936666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.
    Ekwaru JP; Campbell J; Malamba S; Moore DM; Were W; Mermin J
    J Int AIDS Soc; 2013 Apr; 16(1):17355. PubMed ID: 23547778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-financing for viral load monitoring during the course of antiretroviral therapy among patients with HIV/AIDS in Vietnam: A contingent valuation survey.
    Nguyen QL; Nguyen LH; Tran BX; Phan HT; Le HT; Nguyen HD; Tran TD; Do CD; Nguyen CM; Thuc VT; Latkin C; Zhang MW; Ho RC
    PLoS One; 2017; 12(2):e0172050. PubMed ID: 28199405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
    Jain V; Byonanebye DM; Amanyire G; Kwarisiima D; Black D; Kabami J; Chamie G; Clark TD; Rooney JF; Charlebois ED; Kamya MR; Havlir DV;
    AIDS; 2014 Sep; 28(15):2241-9. PubMed ID: 25022596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiretroviral therapy programmes in resource limited settings.
    del Rio C; Armstrong W
    BMJ; 2011 Nov; 343():d6853. PubMed ID: 22074712
    [No Abstract]   [Full Text] [Related]  

  • 26. Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.
    Phillips AN; Cambiano V; Nakagawa F; Bansi-Matharu L; Sow PS; Ehrenkranz P; Ford D; Mugurungi O; Apollo T; Murungu J; Bangsberg DR; Revill P
    PLoS One; 2016; 11(12):e0167654. PubMed ID: 27977702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Home testing and counselling to reduce HIV incidence in a generalised epidemic setting: a mathematical modelling analysis.
    Ying R; Sharma M; Celum C; Baeten JM; van Rooyen H; Hughes JP; Garnett G; Barnabas RV
    Lancet HIV; 2016 Jun; 3(6):e275-82. PubMed ID: 27240790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.
    Estill J; Egger M; Blaser N; Vizcaya LS; Garone D; Wood R; Campbell J; Hallett TB; Keiser O;
    AIDS; 2013 Jun; 27(9):1483-92. PubMed ID: 23462219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of Early vs Late Diagnosis of HIV-Infected Patients in South Carolina.
    Rampaul M; Edun B; Gaskin M; Albrecht H; Weissman S
    South Med J; 2018 Jun; 111(6):355-358. PubMed ID: 29863227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.
    Kimmel AD; Goldie SJ; Walensky RP; Losina E; Weinstein MC; Paltiel AD; Zhang H; Freedberg KA;
    Antivir Ther; 2005; 10(1):41-52. PubMed ID: 15751762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+ cell count at antiretroviral therapy initiation and economic restoration in rural Uganda.
    Venkataramani AS; Thirumurthy H; Haberer JE; Ii YB; Siedner MJ; Kembabazi A; Hunt PW; Martin JN; Bangsberg DR; Tsai AC
    AIDS; 2014 May; 28(8):1221-6. PubMed ID: 24406678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the effects of Artemisia Annua L. and Moringa Oleifera Lam. on CD4 count and viral load among PLWH on ART at Mbarara Regional Referral Hospital: a double-blind randomized controlled clinical trial.
    Twinomujuni SS; Atukunda EC; Mukonzo JK; Nicholas M; Roelofsen F; Ogwang PE
    AIDS Res Ther; 2024 Apr; 21(1):22. PubMed ID: 38627722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends and Determinants of Antiretroviral Therapy Patient Monitoring Practices in Kenya and Uganda.
    Dansereau E; Gakidou E; Ng M; Achan J; Burstein R; DeCenso B; Gasasira A; Ikilezi G; Kisia C; Masters SH; Njuguna P; Odeny TA; Okiro EA; Roberts DA; Duber HC
    PLoS One; 2015; 10(8):e0135653. PubMed ID: 26275151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model for reduced HIV-1 viral load monitoring in resource-limited settings.
    Bryant L; Smith N; Keiser P
    J Int Assoc Provid AIDS Care; 2013; 12(1):67-71. PubMed ID: 22553318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
    Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
    N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.
    Dutta A; Barker C; Kallarakal A
    PLoS Med; 2015 Nov; 12(11):e1001907; discussion e1001907. PubMed ID: 26599990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Choice of time horizon critical in estimating costs and effects of changes to HIV programmes.
    McCreesh N; Andrianakis I; Nsubuga RN; Strong M; Vernon I; McKinley TJ; Oakley JE; Goldstein M; Hayes R; White RG
    PLoS One; 2018; 13(5):e0196480. PubMed ID: 29768457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
    Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
    Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.
    Jain V; Chang W; Byonanebye DM; Owaraganise A; Twinomuhwezi E; Amanyire G; Black D; Marseille E; Kamya MR; Havlir DV; Kahn JG
    PLoS One; 2015; 10(12):e0143433. PubMed ID: 26632823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
    Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
    Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.